Bactiguard Holding AB's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 76.98.
Bactiguard Holding AB's Days Inventory for the
three
months ended in Mar. 2026 was 579.
Bactiguard Holding AB's Days Payable for the
three
months ended in Mar. 2026 was 401.08.
Therefore, Bactiguard Holding AB's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 254.90.
Bactiguard Holding AB (CHIX:BACTBs) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Bactiguard Holding AB Cash Conversion Cycle Related Terms
Bactiguard Holding AB Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BACTBS vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's Cash Conversion Cycle falls into.
Bactiguard Holding AB Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Bactiguard Holding AB's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB (CHIX:BACTBS) has a Cash Conversion Cycle of 254.90 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Bactiguard Holding AB and its competitors.
Is Bactiguard Holding AB's Cash Conversion Cycle too high?
Bactiguard Holding AB's current Cash Conversion Cycle is 254.90. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.39. Bactiguard Holding AB's value of 254.90 is 63% above this industry median. Overall, Bactiguard Holding AB has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's Cash Conversion Cycle compare to ABT and SYK?
Bactiguard Holding AB's Cash Conversion Cycle of 254.90 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.39. Bactiguard Holding AB's value of 254.90 is 63% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.39, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current Cash Conversion Cycle of 254.90 is 63% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Bactiguard Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current Cash Conversion Cycle is 254.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current Cash Conversion Cycle of 254.90. The stock's GF Value™ is kr274.02, compared to a current price of kr128.60 — trading 53.1% below its estimated fair value. The current Cash Conversion Cycle is 254.90 and 63% above the Medical Devices & Instruments industry median of 156.39. Bactiguard Holding AB's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current Cash Conversion Cycle is 254.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 53.1% below its estimated GF Value™ of kr274.02.
Key valuation signals for CHIX:BACTBS:
Cash Conversion Cycle: 254.90
GF Value™: kr274.02 vs. price of kr128.60 (53.1% below fair value)
Industry Position: 63% above the Medical Devices & Instruments median
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
52GF Score
Get the complete analysis for CHIX:BACTBS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
